-
1
-
-
84855806726
-
-
Colon cancer
-
NCCN: Clinical practice guidelines in oncology: Colon cancer. http:// www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I+Agree
-
Clinical practice guidelines in oncology
-
-
-
2
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
-
3
-
-
1842569206
-
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
-
Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
-
(2004)
J Clin Oncol
, vol.22
, pp. 23-30
-
-
Goldberg, R.M.1
Sargent, D.J.2
Morton, R.F.3
-
4
-
-
36048960109
-
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study
-
Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 25:4779-4786, 2007
-
(2007)
J Clin Oncol
, vol.25
, pp. 4779-4786
-
-
Fuchs, C.S.1
Marshall, J.2
Mitchell, E.3
-
5
-
-
42949150908
-
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
-
Cassidy J, Clarke S, Diaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 2006-2012
-
-
Cassidy, J.1
Clarke, S.2
Diaz-Rubio, E.3
-
6
-
-
2142703727
-
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment
-
Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
-
(2004)
J Clin Oncol
, vol.22
, pp. 1209-1214
-
-
Grothey, A.1
Sargent, D.2
Goldberg, R.M.3
-
7
-
-
53749092781
-
Oxaliplatin plus irinotecan compared to irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma
-
Haller D, Rothenberg M, Wong A, et al: Oxaliplatin plus irinotecan compared to irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 26:4544-4550, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 4544-4550
-
-
Haller, D.1
Rothenberg, M.2
Wong, A.3
-
8
-
-
0037531121
-
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
-
Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003
-
(2003)
J Clin Oncol
, vol.21
, pp. 2059-2069
-
-
Rothenberg, M.L.1
Oza, A.M.2
Bigelow, R.H.3
-
9
-
-
33646580151
-
N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU
-
suppl; abstr 3506, 247s
-
Pitot HC, Rowland KM, Sargent DJ, et al: N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU. J Clin Oncol 23:247s, 2005 (suppl; abstr 3506)
-
(2005)
J Clin Oncol
, vol.23
-
-
Pitot, H.C.1
Rowland, K.M.2
Sargent, D.J.3
-
10
-
-
34447255724
-
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial
-
Seymour MT, Maughan TS, Ledermann JA, et al: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370:143-152, 2007
-
(2007)
Lancet
, vol.370
, pp. 143-152
-
-
Seymour, M.T.1
Maughan, T.S.2
Ledermann, J.A.3
-
11
-
-
34547097252
-
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): Intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
-
Ashley AC, Sargent DJ, Alberts SR, et al: Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): Intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer 110:670-677, 2007
-
(2007)
Cancer
, vol.110
, pp. 670-677
-
-
Ashley, A.C.1
Sargent, D.J.2
Alberts, S.R.3
-
12
-
-
53749096264
-
Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials
-
suppl; abstr 4008, 180s
-
Sargent DJ, Marsoni S, Thibodeau SN, et al: Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 26:180s, 2008 (suppl; abstr 4008)
-
(2008)
J Clin Oncol
, vol.26
-
-
Sargent, D.J.1
Marsoni, S.2
Thibodeau, S.N.3
-
13
-
-
84871470012
-
-
Bertagnolli MM, Compton CC, Niedzwiecki D, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. ASCO Meeting Abstracts 24:541s, 2006 (suppl; abstr 10003)
-
Bertagnolli MM, Compton CC, Niedzwiecki D, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. ASCO Meeting Abstracts 24:541s, 2006 (suppl; abstr 10003)
-
-
-
-
14
-
-
53749099787
-
Impact of microsatellite instability and p53 expression on stage III colon cancer disease-free survival in patients treated by fluorouracil and leucovorin with or without oxaliplatin
-
suppl; abstr 15017, 645s
-
Zaanan A, Cuilliere-Dartigues P, Parc Y, et al: Impact of microsatellite instability and p53 expression on stage III colon cancer disease-free survival in patients treated by fluorouracil and leucovorin with or without oxaliplatin. J Clin Oncol 26:645s, 2008 (suppl; abstr 15017)
-
(2008)
J Clin Oncol
, vol.26
-
-
Zaanan, A.1
Cuilliere-Dartigues, P.2
Parc, Y.3
|